2. Inflammation/Immunology

Inflammation/Immunology (炎症/免疫)

Inflammation/Immunology

関連製品

PDF 93.1 MB

The diseases caused by disorders of the immune system fall into two broad categories: immunodeficiency and autoimmunity. Immunotherapy is also often used in the immunosuppressed (such as HIV patients) and people suffering from other immune deficiencies or autoimmune diseases. This includes regulating factors such as IL-2, IL-10, IFN-α. Infection with HIV is characterized not only by development of profound immunodeficiency but also by sustained inflammation and immune activation. Chronic inflammation as a critical driver of immune dysfunction, premature appearance of aging-related diseases, and immune deficiency.

製品番号 製品名 CAS 番号 純度 構造式
  • HY-162244
    COX-2-IN-40 444790-64-1 98%
    COX-2-IN-40 (compound 17) is a COX-2 inhibitor with the IC50 of 14.86 μM. COX-2-IN-40 can be used for study of chronic pain.
    COX-2-IN-40
  • HY-162264
    Tubulin polymerization/V-ATPase-IN-1 3032401-72-9 98%
    Tubulin polymerization/V-ATPase-IN-1 (compound F10) is a Tubulin polymerization/V-ATPase inhibitor. Tubulin polymerization/V-ATPase-IN-1 shows robust antiproliferation activity against four human cancer cell lines, and exerts antiproliferative activity by inhibiting tubulin and V-ATPase. Tubulin polymerization/V-ATPase-IN-1 induces immunogenic cell death in addition to apoptosis, and inhibits tumor growth in an RM-1 homograft model with enhanced T lymphocyte infiltration.
    Tubulin polymerization/V-ATPase-IN-1
  • HY-162268
    MALT1-IN-13 3032823-58-5 98%
    MALT1-IN-13 (compound 10m) is inhibitor for mucosa-associated lymphoid tissue lymphoma translocation protein 1 (MALT1), which to binds MALT1 protease covalently and irreversibly, inhibits MALT1 with the IC50 of 1.7 μM. MALT1-IN-13 inhibits proliferation against ABC-DLBCL and induces apoptosis in ABC-DLBCL HBL1. MALT1-IN-13 regulates mTOR and PI3K-Akt pathways.
    MALT1-IN-13
  • HY-162269
    Nampt activator-5 3041005-21-1 98%
    Nampt activator-5 is a NAMPT activator with a KD value of 6.19 μM. Nampt activator-5 activates the rate-limiting enzyme in NAD+ biosynthesis and promotes NAD+ production. Nampt activator-5 delays the senescence process of senescent hepatocytes, extends the lifespan of *Caenorhabditis elegans*, and alleviates age-related dysfunction and abnormal biomarkers in naturally aged mice. Nampt activator-5 can be used in aging research.
    Nampt activator-5
  • HY-162316
    NF-κB-IN-15 98%
    NF-κB-IN-15 (compound 14r) is a potent NF-κB inhibitor. NF-κB-IN-15 decreases the NO levels and inhibits the release of IL-6, TNF-α, and IL-1β in LPS (HY-D1056) -induced cells. NF-κB-IN-15 inhibits LPS-induced phosphorylation of p65 and degradation of IκBα. NF-κB-IN-15 shows anti-inflammatory activity has the potential for the research of acute lung injury (ALI).
    NF-κB-IN-15
  • HY-162329
    Antibacterial agent 195 98%
    Antibacterial agent 195 (compound A20), a Matrine (HY-N0164) derivative, is a potent antibiotic. Antibacterial agent 195 shows antibacterial activity against Gram-positive bacterium (MICS.aureus=0.021 mg/mL; MICP.acnes=0.030 mg/mL), Gram-negative bacterium (MICE.coli=0.092 mg/mL; MICC.albicans=0.379 mg/mL) and Fungus (MIC=2.806 mg/mL).
    Antibacterial agent 195
  • HY-162331
    STING Degrader-1 98%
    STING Degrader-1 (compound 2), a molecular glue, is a potent STING degrader that covalently binds to STING and E3 ligase. STING Degrader-1 exhibits a "hook effect", that degrades 75% STING protein at 10 μM, and degrades ca. 30% STING protein at 30 μM.
    STING Degrader-1
  • HY-162343
    PD-1/PD-L1-IN-41 98%
    PD-1/ PD-L1-in-41 (Compound 5c) is a PD-L1 and PD-1 inhibitor with IC50 value of 10.2 nM.
    PD-1/PD-L1-IN-41
  • HY-162378
    LT-630 98%
    LT-630 is a HDAC6 inhibitor. LT-630 ameliorates liver injury by reducing oxidative damage.
    LT-630
  • HY-162385
    COX-2-IN-42 98%
    COX-2-IN-42 (Compound T1) is a COX-2 inhibitor, and protects zebrafish against PTZ-induced neuronal damage.
    COX-2-IN-42
  • HY-162398
    LQ23 2997615-62-8 98%
    LQ23 is a selective inhibitor for CDC2-like kinase 2 (CLK2) with an IC50 of 1.4 nM. LQ23 exhibits anti-inflammatory activity.
    LQ23
  • HY-162399
    PD-L1-IN-6 98%
    PD-L1-IN-6 (Compound 16) is an orally active inhibitor for PD-L1 expression in neutrophil by targeting STAT3 with KD of 90.5 nmol/L. PD-L1-IN-6 promotes neutrophil-mediated antifungal immunoresponse.
    PD-L1-IN-6
  • HY-162404
    (14S,15R)-14-Deoxyoxacyclododecindione 1899061-36-9 98%
    (14S,15R)-14-Deoxyoxacyclododecindione (Compound 3) acts as an inhibitor of TGF-β-dependent Smad2/3 and IL-4-dependent STAT6, with IC50 values of 90 nM and 20 nM, respectively. (14S,15R)-14-deoxyoxacyclododecindione is a potent IL-4 inhibitor with an IC50
    value of 20 nM. (14S,15R)-14-Deoxyoxacyclododecindione is applicable to the research of chronic inflammation and fibrotic diseases.
    (14S,15R)-14-Deoxyoxacyclododecindione
  • HY-162405
    STAT6-IN-12 2949393-27-3 98%
    STAT6-IN-12 is a potent STAT6 inhibitor with an IC50 of 50 nM. STAT6-IN-12 also inhibits Smad2/3 with an IC50 of 68 nM. STAT6-IN-12 inhibits TGFβ-dependent Smad2/3 signaling pathway, IL-4-dependent STAT6 signaling pathway, and cellular inflammatory responses. STAT6-IN-12 can be used for the research of inflammation.
    STAT6-IN-12
  • HY-162425
    Anti-inflammatory agent 78 98%
    Anti-inflammatory agent 78 (compound L-37) is a potent anti-inflammatory agent. Anti-inflammatory agent 78 has significant potency on PGE2, PGE1, COX-2 and COX-1 inhibition. Anti-inflammatory agent 78 can inhibits NO release in LPS-stimulated RAW 264.7 cell line.
    Anti-inflammatory agent 78
  • HY-162458
    Antifungal agent 100 2975157-18-5 98%
    Antifungal agent 100 (compound 3i) exhibits significant antifungal effects against S. sclerotiorum with an EC50 value of 0.33 mg/L. Antifungal agent 100 displays an IC50 of 0.63 mg/mL against the Succinate dehydrogenase (SDH) of S. sclerotiorum.
    Antifungal agent 100
  • HY-162459
    cGAS-IN-3 98%
    cGAS-IN-3 (compound 30d-S) is an orally active cyclic GMP-AMP synthase (Cyclic GMP-AMP Synthase/cGAS) inhibitor with good plasma exposure and low clearance. cGAS-IN-3 has anti-inflammatory activity and can significantly reduce lung inflammation in rats.
    cGAS-IN-3
  • HY-162482
    EGFR kinase inhibitor 5 98%
    EGFR kinase inhibitor 5 (Compound 4c) is an orally active inhibitor for epidermal growth factor receptor (EGFR) kinase, with IC50 of 18.35 μM. EGFR kinase inhibitor 5 induces apoptosis. EGFR kinase inhibitor 5 exhibits anticancer and anti-inflammatory activity with low toxicity (LD50 range: 500-2000 mg/kg).
    EGFR kinase inhibitor 5
  • HY-162483
    EGFR kinase inhibitor 6 98%
    EGFR kinase inhibitor 6 (Compound 4b) is an orally active inhibitor for epidermal growth factor receptor (EGFR) kinase, with IC50 of 24.34 μM. EGFR kinase inhibitor 6 induces apoptosis. EGFR kinase inhibitor 6 exhibits anticancer and anti-inflammatory activity with low toxicity (LD50 range: 500-2000 mg/kg).
    EGFR kinase inhibitor 6
  • HY-162490
    TF-S14 2425563-60-4 98%
    TF-S14 is a reverse agonist of RORγt. TF-S14 reduces Th17 cell-associated cytokine production, including IL-17A, IL-21, and IL-22 by binding to and inhibiting RORγt activity. TF-S14 can be used in the study of autoimmune diseases and rejection in allotransplantation.
    TF-S14
製品番号 製品名 / Synonyms Application Reactivity